CY1124507T1 - Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων - Google Patents

Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων

Info

Publication number
CY1124507T1
CY1124507T1 CY20211100757T CY211100757T CY1124507T1 CY 1124507 T1 CY1124507 T1 CY 1124507T1 CY 20211100757 T CY20211100757 T CY 20211100757T CY 211100757 T CY211100757 T CY 211100757T CY 1124507 T1 CY1124507 T1 CY 1124507T1
Authority
CY
Cyprus
Prior art keywords
viral
infection
therapeutic treatment
bacterial infections
mek inhibitor
Prior art date
Application number
CY20211100757T
Other languages
English (en)
Inventor
Stephan Ludwig
Oliver Planz
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Publication of CY1124507T1 publication Critical patent/CY1124507T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στο PD-0184264 για χρήση σε μια μέθοδο για την προφύλαξη ή/και τη θεραπεία μιας συν-μόλυνσης που περιλαμβάνει μια βακτηριακή λοίμωξη και μια λοίμωξη από τον ιό της γρίπης ή μια ιική ή βακτηριακή λοίμωξη μόνο. Επίσης παρέχονται συνθέσεις όπως αναστολείς για χρήση στην προφύλαξη ή/και τη θεραπεία μιας συν-μόλυνσης που περιλαμβάνει μια βακτηριακή λοίμωξη και μια λοίμωξη από τον ιό της γρίπης ή μια βακτηριακή ή ιική λοίμωξη μόνο.
CY20211100757T 2017-10-17 2021-08-24 Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων CY1124507T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17
PCT/EP2018/078335 WO2019076947A1 (en) 2017-10-17 2018-10-17 NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
CY1124507T1 true CY1124507T1 (el) 2022-07-22

Family

ID=60484427

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100757T CY1124507T1 (el) 2017-10-17 2021-08-24 Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων

Country Status (21)

Country Link
US (1) US11903917B2 (el)
EP (2) EP3973960A1 (el)
JP (2) JP7227967B2 (el)
KR (1) KR20200072499A (el)
CN (1) CN111479566B (el)
AU (1) AU2018351475A1 (el)
BR (1) BR112020007442A2 (el)
CA (1) CA3078424A1 (el)
CY (1) CY1124507T1 (el)
DK (1) DK3697405T3 (el)
EA (1) EA202090693A1 (el)
ES (1) ES2883639T3 (el)
HR (1) HRP20211252T1 (el)
HU (1) HUE055738T2 (el)
LT (1) LT3697405T (el)
MX (2) MX2020003473A (el)
PL (1) PL3697405T3 (el)
PT (1) PT3697405T (el)
SI (1) SI3697405T1 (el)
WO (1) WO2019076947A1 (el)
ZA (1) ZA202002069B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021037956A1 (en) 2019-08-27 2021-03-04 Atriva Therapeutics Gmbh Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
KR20220079573A (ko) * 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
HUP0202623A3 (en) 1999-07-16 2003-03-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
DE10300222A1 (de) 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
US20150141380A1 (en) * 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
JP6294889B2 (ja) 2012-10-08 2018-03-14 アトリバ セラピューティクス ゲーエムベーハー ウイルス疾患の処置におけるｍｅｋ阻害物質
CN116942832A (zh) 2014-05-16 2023-10-27 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
KR20220079573A (ko) 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
EP3912623A1 (en) 2020-05-20 2021-11-24 Atriva Therapeutics GmbH Mek-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
CN111479566B (zh) 2024-05-07
BR112020007442A2 (pt) 2020-10-27
SI3697405T1 (sl) 2021-11-30
CA3078424A1 (en) 2019-04-25
DK3697405T3 (da) 2021-08-23
KR20200072499A (ko) 2020-06-22
PL3697405T3 (pl) 2021-12-13
ZA202002069B (en) 2021-10-27
JP2023058631A (ja) 2023-04-25
PT3697405T (pt) 2021-08-27
AU2018351475A1 (en) 2020-04-30
EP3697405B1 (en) 2021-07-14
CN111479566A (zh) 2020-07-31
US20200289445A1 (en) 2020-09-17
MX2022016066A (es) 2023-02-02
MX2020003473A (es) 2020-10-01
HRP20211252T1 (hr) 2021-11-12
EP3697405A1 (en) 2020-08-26
WO2019076947A1 (en) 2019-04-25
HUE055738T2 (hu) 2021-12-28
JP7227967B2 (ja) 2023-02-22
ES2883639T3 (es) 2021-12-09
JP2020537659A (ja) 2020-12-24
EP3973960A1 (en) 2022-03-30
EA202090693A1 (ru) 2020-10-19
US11903917B2 (en) 2024-02-20
LT3697405T (lt) 2021-10-25

Similar Documents

Publication Publication Date Title
CY1124507T1 (el) Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1121040T1 (el) Aντιικη θεραπεια
CY1124829T1 (el) Παραγωγα 4'-υπoκαταστημενων νουκλεοζιδιων ως αναστολεις αντιστροφης μεταγραφασης hiv
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
EA201692303A1 (ru) Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
EA201791576A1 (ru) Ингибитор jak
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
CY1120607T1 (el) Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
CY1123189T1 (el) Αντιμικροβiακο πεπτιδιο
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
BR112018071048A2 (pt) combinações e métodos que compreendem um inibidor da montagem de capsídeos
CY1124406T1 (el) Αζασετρονη για χρηση στη θεραπεια της απωλειας ακοης
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
CY1121924T1 (el) Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna